NATCO Pharma Q4 profit rises 5% YoY to ₹406 crore, margin expands; check all details

The drug maker's revenue from operations stood at ₹1,086 crore in the quarter under review, jumping 14.3% YoY from ₹1,086 crore in the fourth quarter of FY24. The company generated ₹1,206 crore in Q4FY25, rising 12.23% YoY from ₹1,074.6 crore in the year-ago period. Furthermore, its revenue from the agrochemical business was at ₹15 crore, as against a negative revenue of ₹63 crore in Q4FY24.

In the January-March FY25 quarter, the company faced an impairment loss of ₹50 crore on the property, plant and equipment of the agrochemical segment.

NATCO Pharma’s earnings before interest, tax, depreciation and amortisation (EBITDA) rose by 10.2% YoY to ₹548 crore in the fourth quarter of FY25. In the year-ago period, it stood at ₹497.3 crore.

The drug manufacturer’s EBITDA margin expanded to 44.89% from 46.55% in Q4FY24.

NATCO Pharma stock performance

Shares of NATCO Pharma closed in the negative territory at ₹862.30, down 1.86% on the NSE on Wednesday. It also fell 2.12% to an intra-day low of ₹860. However, the company announced its results after market hours.

The stock lost 1.86% over the past three days but gained 1.34% since the beginning of May. The scrip has plunged 37.84% on a year-to-date basis.

The share hit a 52-week low of ₹726.80 apiece on April 7, 2025, and a high of ₹1,639 on September 12, 2024.

NATCO Pharma has a total market capitalisation of ₹15,546.74 crore, as of May 28, 2025, on the NSE.